Home Blog

Supported Content – The Pharmaceutical Journal


Our approach

A partnership with Pharmaceutical journal allows the creation of available for free, high quality, independent learning material, which will help achieve the goals of both organizations.

More specifically, these learning materials exclusively developed and adapted:

  • Educate and support pharmacists by providing them with the best clinical advice to enable skill and provide trust at improve patient care;
  • Increase awareness among the pharmacy teams of partner brands, products and services and offer recognition as a partner for supporting the profession of pharmacist;
  • Position promotional material and advertising in relation to editorial content.

Our approach is fully compliant with the ABPI and PAGB codes of practice.

Case Study – Pharmacy Learning Center: Joint Pain

The Pharmacy Learning Center on Joint Pain is the result of a partnership between Pharmaceutical journal and GSK. Together, we aim to provide free and open resources to pharmacy teams to better serve patients seeking joint pain counseling.

We bring together editorial learning content produced for Pharmaceutical journal and complement that with newly commissioned articles and content, produced with financial support from GSK. Our partner, GSK, also has the opportunity to position their educational material explaining the value of the work and products they produce for patients.

The Pharmacy Learning Center is at the heart of our mission to provide pharmacists with valuable advice and support their daily practice.

Supported content

Single items

Articles written by independent and editorial independent experts, promoting evidence-based best practices.

Content is ordered by Pharmaceutical journal with the editorial scope and design agreed with the partner. Pharmaceutical journal retains exclusive editorial responsibility, and the partner is clearly declared as a sponsor – providing support for free and open access. Upon posting, content is promoted across all of our digital channels.


We can plan, develop and market editorial and customer-controlled multimedia in the form of podcasts and videos. Take a look at some of our past work below.

Gino Martini, Chief Scientist at the Royal Pharmaceutical Society, Appears in Our Sponsored Pain Management Video

Membership survey

We can work with partners to co-design and develop a survey that will provide detailed information on the understanding of Royal Pharmaceutical Society member pharmacists and current pharmaceutical practice in Britain.

What we do :

  • Work with independent experts alongside our partners to guide the development of the survey;
  • Conduct a survey of the target audience of RPS members;
  • Analyze results and metrics, and provide a report to the partner that provides recommendations and identifies journalism content and topic to meet all learning needs and requirements, in addition to raw data.

Printed supplements

An editorial supplement or pharmacy guide provides a comprehensive, engaging and authoritative overview of a hot topic in pharmacy or pharmaceutical science. Pharmaceutical journal The editorial team assigns the best scientific and medical writers and opinion leaders to contribute to a collection of original articles.

The Supplements are a unique resource of free and valuable learning materials delivered to a highly influential audience of pharmacists and position partners as a forward-looking company; leader of new developments in one of its priority areas.

The cover will recognize your support and this partnership explained in an accompanying editorial.

Multimedia event or round table

A virtual panel of experts gathered to discuss or make a presentation that promotes common goals around the safe and effective use of medicines and puts pharmacy at the forefront of healthcare.

Partners can suggest key opinion leaders, and Pharmaceutical journal identify and invite experts, facilitate presentations if necessary, participate as expert advisor and report.

After the event, a report or recording published online and promoted on our digital channels.

For any Supported Content requests, please contact:
Jack rendell Digital Sales Manager
+44 (0) 207 572 2406

Source link

Molnupiravir Shows “Promising” Results in Phase 3 Trials: Optimus Pharma


The interim results of phase 3 capsules of Molnupiravir, a Covid-19 drug, showed “promising” results, Optimus Pharma announced on Wednesday.

“The drug was successful in effectively reducing viral load with RT-PCR negativity reaching 78.3% in the test arm versus 48.4% in the standard care arm on day 5,” the company said in a report. communicated.

Day 10 and day 14 of the course of treatment also gave excellent results in which the remaining patients were successful in achieving RT-PCR negativity, he added.

In accordance with the approved clinical trial protocol, 1,218 subjects with mild Covid-19 will be randomized into the study in a 1: 1 ratio to Molnupiravir with standard management or management alone. The duration of treatment is a maximum of five days and the total duration of the study will be a maximum of 28 days from randomization.

According to Dr. Srinivasa Reddy, Charman and Managing Director of Optimus Pharma, his company has internally developed the active pharmaceutical ingredient (API) and product formulations and has obtained approval to conduct a Phase 3 clinical trial.

“Optimus is ready to immediately start manufacturing Molnupiravir for Covid-19 patients in India,” he added.

“The trial also reveals clinical improvement in a significantly high proportion of patients’ health. The safety of the drug has also been established with no side effects, comorbidity or morbidity observed during and after the course of treatment, ”said Reddy.

Optimus has contacted the Drugs Controller General of India (DCGI) to request emergency use authorization for Molnupiravir in India.

Source link

2021 US Pharmaceutical and Healthcare Industry Analysis and Forecast Report – ResearchAndMarkets.com


DUBLIN – (COMMERCIAL THREAD)–The “Pharmaceutical and Healthcare Industry in the United States – Forecast and Analysis 2021” report was added to ResearchAndMarkets.com offer.

With COVID-19 having severely impacted various industries in the United States, it is difficult to accurately predict how the pharmaceutical and healthcare market will perform in a short period of time. However, there is no doubt that the pharmaceutical and healthcare sector has been severely affected. With the economic slowdown setting in due to the pandemic, the U.S. pharmaceutical and healthcare industry is expected to slow in the near term.

The US pharmaceutical industry is a highly globalized industry dominated by multinational corporations with significant commercial activity in many countries and whose products are distributed and marketed around the world. In recent decades, the industry has undergone dramatic structural changes, with the boom in the biotechnology sector, substantial growth in demand driven by demographics and the substitution of other therapeutic modalities such as surgery, and increased competition from globally active generic manufacturers.

The report covers the following data:

  • In-depth coverage of the pharmaceutical and healthcare industry in the United States by sectors as well as an analysis of how the COVID-19 pandemic is affecting the industry.

  • We analyze the Prescription Drugs, Generic Drugs, Over the Counter Drugs segments and also analyze the clinical trials landscape in the United States.

  • A SWOT analysis of the pharmaceutical and healthcare industry in the United States.

  • A strategic analysis of Porter’s five forces on the U.S. healthcare and pharmaceutical industry is included and examines the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and substitution in the industry. ‘industry.

  • We take a close look at the regulatory framework governing the pharmaceutical and healthcare industry in the United States.

  • Competition in the industry, as well as an in-depth analysis of major players like AstraZeneca, Eli Lilly, Glaxo Smith Kline and many more are included.

Main topics covered:

A. Executive summary

B. Definition of industry

C. Pharmaceutical and healthcare industry in the United States

C.1 Impact of COVID-19 on the industry

C.2 Analysis of the pharmaceutical sector

C.3 Health sector analysis

C.4 Prescription drug market

C.5 Patented medicine market

C.6 Market for over-the-counter drugs

C.7 Generic drug market

C.8 Clinical trials in the United States

D. Pharmaceutical and healthcare industry in the United States: SWOT analysis

D.1 Forces on which to build

D.2 Weaknesses to overcome

D.3 Opportunities to be exploited

D.4 Threats to be overcome

E. The American Pharmaceutical Industry: Analysis of Porter’s Five Forces Strategy

E.1 Bargaining power of buyers

E.2 Bargaining power of suppliers

E.3 Competitive Rivalry in Industry

E.4 Threat of new entrants

E.5 Threat of substitutes

F. Chronic medical conditions in the United States

F.1 Overview

F.2 Alzheimer’s disease

F.3 Arthritis

F.4 Cancer

F.5 Cardiovascular disease

F.6 Diabetes

F.7 Obesity

G. Industry regulatory framework

G.1 Overview

G.2 New Drug Regulations

G.3 U.S. Health Care Law

G.4 Other regulations

G.4.1 Prescription Drug User Fees Act

G.4.2 Regulations governing generic drugs

G.4.3 Bolar Amendment

G.4.4 Regulations governing biosimilars

G.4.5 Regulations Governing Over-the-Counter Drugs

G.4.6 Tax reform project

G.4.7 Pricing and reimbursement regime

G.4.8 Proposition 61 – The California Drug Price Relief Act

G.4.9 Senate Bill 17

G.4.10 Regulations governing the promotion of pharmaceutical products

G.4.11 What does the landscape of payers look like?

G.5 Challenges with intellectual property rights

H. Import / Export of pharmaceutical products

I. Competition in industry

I.1 Competitive landscape

I.2 Impact of COVID-19 on competition

I.3 Impacts on competition

I.4 Competition in the generic drug sector

I.5 Competition in the US pharmaceutical sector

I.6 Competition in the US drug distribution market

J. Forecast: Pharmaceutical and healthcare industry in the United States

J.1 Prospects for the US pharmaceutical industry

J.2 US Healthcare Industry Outlook

J.3 Outlook for the prescription drug sector

J.4 Patented Medicines Market Outlook

J.5 OTC Drug Market Outlook

J.6 Generic Drugs Market Outlook

K. Pharmaceutical and health industry: major players

  • AbbVie

  • Amgen

  • Apotex

  • AstraZeneca

  • Bristol Myers Squibb

  • Eli Lilly and company

  • Gilead Sciences

  • GlaxoSmithKline

  • Johnson & johnson

  • Merck & Co.

  • Novartis

  • Pfizer

  • Sanofi SA

  • Teva Pharmaceutical Industries Ltd.

For more information on this report, visit https://www.researchandmarkets.com/r/1qhj68

Source link

Non-textile exports post double-digit growth in FY21 – Journal


ISLAMABAD: Pakistan’s non-textile exports increased 11.7% year-on-year to $ 9.904 billion in 2020-2021 due to the partial resumption of international orders and government support programs.

The overall growth of the non-textile sector is mainly driven by value-added sectors. The non-textile sector has yet to receive full orders at pre-Covid levels, data compiled by the Pakistan Bureau of Statistics (PBS) showed.

In FY21, three sectors – leather garments, surgical instruments and engineered products – sustained growth in export earnings despite lockdowns in many countries. In the value-added leather sector, exports of leather garments increased by 14.02 pc and leather gloves by 22.26 pc respectively. Exports of rawhide fell by more than 12.04% in FY21, mainly showing that it is used in domestic value-added industries.

Pakistan is one of the world’s leading suppliers of surgical instruments. However, these instruments are remarketed from Western countries with well-known brands. As a result, the export value of these products remains much lower.

Exports of surgical instruments grew 20.36 percent to $ 428.008 million in FY21 from $ 355.617 million last year, followed by a 28.46 percent jump in pharmaceuticals at $ 270.142 million compared to $ 210.299 million last year.

Footwear exports increased 4.72% year-on-year to $ 131.889 million, driven by leather and canvas footwear. Exports of engineering products grew 30.91% year-on-year to $ 226.024 million in FY21, followed by 37.60% of electric fans to $ 32.444 million and cement by 3, 26% to $ 267.910 million on an annual basis.

In the 2021-2022 budget, the government proposed several measures, including a reduction in tariffs on raw materials to promote exports of value-added pharmaceuticals, plastics, chemicals, engineering and textiles.

Food shortages in the domestic market and lower demand in the international market have resulted in an overall decline in demand for Pakistani food products, especially fruit.

Data compiled by the PBS showed the food basket grew paltry 0.74% in the outgoing fiscal year to $ 4.393 billion year-on-year.

In this category, rice exports fell by 6.17 pc. On the other hand, basmati exports fell by 26.51 pc in value and 27.35 pc in quantity, while non-basmati exports increased by 5.26 pc in value.

Spice exports increased by 5.34pc, followed by oilseeds, nuts 212.64pc, meat and products by 9.62pc, fish and fishery products by 1.85pc during the period under review. On the contrary, exports of overseas sales of vegetables up 7.14pc, fruit 11.16pc, tobacco 0.49pc.

Posted in Dawn, July 21, 2021

Source link

Northern Colorado business people petition governor to end supplemental unemployment payments


A group of about 170 business people from Northern Colorado has signed a letter asking Gov. Jared Polis to end now the special unemployment benefits that are not set to expire until September.

The signers, as noted in the letter, believe that the benefits are keeping some people from returning to work at a time when businesses are trying to operate at full capacity but unable to find people to fill positions. Others, however, say eliminating the payments won’t necessarily cause people to return to work if other factors have greater significance to them.

“Our economy is booming in Colorado, but our small businesses are constrained by the lack of available workers. We are asking Gov. Polis to rescind the voluntary extended federal unemployment benefits of $ 300 extra per week, ”Pete Gazley, president of Total Facility Care, a building maintenance company in Northern Colorado, said in a written statement. “There are more jobs than workers, so removing this would incentivize people to get back into the workforce. As the state has opened, we believe it is safe to return to work. Fears over coronavirus can be easily overcome with the easy accessibility of the vaccine and what are now common safety practices, ”he said.

“We are in a new place in our economy, and we need to be doing everything we can to ensure we are getting people back to work. In health care, if we don’t have the strong workforce to serve our patients and clients, then we all suffer, ”said Yvonne Myers, health systems director at Columbine Health Systems.

The letter to the governor admits that the move may be controversial. About half the states, especially those led by Republican governors, have already eliminated or plan to eliminate the bonus federal unemployment payments.

Some national studies, including one by the Federal Reserve Bank of Chicago and another by the University of Chicago, question the impact of doing so, saying that other factors such as pay rates and COVID fears also affect the decision to return to work.

Francisca Antman, an economist at the University of Colorado who specializes in labor economics, economic development and public economics, told BizWest that eliminating the supplemental payments may cause some to return to work but the jury is still out on whether other factors are having a bigger impact. Those factors might be the concern of some about getting sick or because they are caring for children or people who are immunocompromised.

“Theoretically, any non-labor income would have an impact [on return to work], ”She said. “This is a health pandemic, and unemployment is tied to that. There are a lot of other factors to consider. If more people get sick, that affects the economy, also. ”

[We can’t just say] “If it’s suppressing employment we shouldn’t do it [provide supplemental payments]. Further assistance also stimulates the economy, ”she said.

She said experiences in other states might provide some insight on whether eliminating the supplemental payments work. “We’re going to know soon when the payments expire,” she said.

Martin Shields, economist at Colorado State University, said research on the topic is still developing, but he cited a Yale study that concluded, “We find no evidence that more generous benefits disincentivized work either at the onset of the expansion or as firms looked to return to business over time.”

© 2021 BizWest Media LLC

Source link

Opioid lawsuits in US on brink of settlement with 4 companies


The multi-year effort by state and local governments in the United States to force the pharmaceutical industry to help pay for a national crisis of opioid addiction and overdose took a big step forward on Tuesday when lawyers for the governments Locals announced they were on the verge of a $ 26 billion settlement with the nation’s three largest drug distribution companies and drug maker Johnson & Johnson.

Under the deal, Johnson & Johnson would produce no opioids for at least a decade. And AmerisourceBergen, Cardinal Health and McKesson are sharing prescribing information as part of a new system to stop avalanches of pills that arrived in some areas about a decade ago.

Lawyers for local governments said all details could be shared within days. That wouldn’t be the end of the matter though; each state would have 30 days to decide whether or not to join. And local governments will have five months after that to decide. If governments do not participate, the total number of regulations would decrease.

“This is a national crisis and it could and should have been addressed perhaps by other branches of government,” said Paul Geller, one of the leading lawyers representing local governments in the United States, on Tuesday. United, during a conference call with journalists. “But this is really an example of the use of litigation to settle a national problem.”

If approved, the settlement will likely be the most significant of many settlements in opioid litigation. While this will mean billions for the lawyers who have worked on the cases, it is expected to add over $ 23 billion to reduction and mitigation efforts to help secure treatment for people with drug addiction as well as other programs for deal with the crisis. The money would come in 18 annual installments, with the largest amounts over the next several years.

The deal echoes the one that companies have been advocating, sometimes in public, for two years.

Johnson & Johnson reiterated in a statement that they are prepared to contribute up to $ 5 billion to the national settlement.

“There continues to be progress towards finalizing this agreement and we remain committed to providing certainty to parties involved and essential assistance to families and communities in need,” the company said. “The settlement is not an admission of liability or wrongdoing, and the Company will continue to defend itself against any disputes that the final agreement does not resolve.”

But Cardinal Health declined to comment early Tuesday, and other distribution companies did not respond to requests for comment.

Associated Press tally reveals there have been at least $ 40 billion in settlements, penalties and fines made or proposed between governments and the opioid record since 2007, not counting one between the federal government and OxyContin maker Purdue Pharma in which most of the $ 8.3 billion would be raised. Purdue tries to strike deal in bankruptcy court it could be worth $ 10 billion over time; a hearing on this plan is scheduled for August.

Other offers are possible. While a growing number of companies in the industry have made deals, some manufacturers have not – and no pharmaceutical company has made deals nationwide.

But the total amount in the settlements is well below estimates of the financial costs of the outbreak. The Society of Actuaries found the cost of the crisis in the United States to be $ 630 billion from 2015 to 2018, most of the costs being borne by the private sector. And the White House Council of Economic Advisers, when examining the economic impact of people who fatally overdosed, put the cost of a year at around $ 500 billion nationwide..

Unlike tobacco colonies Reached in the 1990s, governments agreed to spend the money they brought back from opioid regulations to deal with the opioid crisis.

In a joint statement, the attorneys general of Connecticut, Delaware, Florida, Louisiana, Massachusetts, New York, North Carolina, Ohio, Pennsylvania and Tennessee said the Settlement talks with the four companies were “potentially close to completion,” and that “we look forward to bringing much-needed dollars back to our states to help people recover from opioid addiction and fundamentally change the opioid manufacturing and distribution industries so that it doesn’t happen again.

But they still have choices ahead of them on how they do it.

“Is this a good piece of change? Asked Ryan Hampton, who is recovering from an opioid addiction and campaigning in Las Vegas for policy to deal with the overdose crisis. “Of course it is. Will he get where he needs to go? The jury is still out on that.

Even before the settlement plan was unveiled on Tuesday, a group of public health advocates and experts began calling for all settlement money to be spent to address the opioid crisis.

“It’s money that can do a lot of good if used well,” said Joshua Sharfstein, associate dean of the Johns Hopkins Bloomberg School of Public Health, which is leading the effort. “It is really important to use it well to save lives because it comes at the height of the overdose epidemic. “

Private attorneys on the plaintiffs’ executive committee representing local governments in opioid lawsuits across the country announced some details of the settlement on Tuesday before it was even completed. The decision to do so is due in part to the fact that New York State reached an agreement on Tuesday with the Big Three distribution companies in a lawsuit in a Long Island state court. .

The New York deal, worth more than $ 1 billion, represents the portion of the national deal it will receive from distributors if the national deal is finalized. New York also struck a similar deal last month with Johnson & Johnson worth $ 230 million..

“Today we hold them accountable for providing more than $ 1 billion more to opioid-ravaged New York communities for treatment, recovery and prevention efforts,” said the New York attorney general. York, Letitia James, in a statement Tuesday.

The lawsuit is expected to continue, but the settlement leaves only three drugmakers as defendants.

Other manufacturers, regional distribution companies and drugstores will remain in New York and in other cases for now. Final arguments in a West Virginia lawsuit against the distributors are expected to proceed as scheduled next week. On-site attorney general Patrick Morrisey said the state is unlikely to agree to the terms.

“I will continue to fight to protect West Virginia and I will not allow the big states to dictate how we hold the accused accountable for their actions,” he said in a statement Tuesday.

State and local governments say distribution companies did not have proper controls to report or stop shipments to pharmacies that received disproportionate shares of potent and addicting prescription pain relievers. The companies have maintained that they are filling legal drug orders placed by doctors – so they should not be blamed for the drug abuse and overdose crisis in the country.

An Associated Press analysis of federal distribution data found that enough prescription opioids were shipped in 2012 for everyone in the United States to have a 20-day supply.

And opioids – including prescription drugs and illegal drugs like illicitly produced heroin and fentanyl – have been linked to more than 500,000 deaths in the United States since 2000. The number of cases reached an all-time high in 2020.


Associated Press writer Cuneyt Dil in Charleston, West Virginia, contributed to this report.

Source link

Is Spectrum Pharmaceuticals, Inc. (SPPI) a good buy in the healthcare industry?


Spectrum Pharmaceuticals, Inc. (30) is at the top of the healthcare industry according to Investors Observer. SPPI received an overall rating of 30, which means it scores over 30% of the stocks. Additionally, Spectrum Pharmaceuticals, Inc. scored 85 in the healthcare industry, ranking it above 85% of healthcare stocks.

SPPI has an overall score of 30. Find out what that means to you and get the rest of the leaderboard on SPPI!

What do these notes mean?

Finding the best stocks can be tricky. It is not easy to compare companies from all industries. Even companies in the healthcare industry can sometimes be difficult to compare. Investors ObserverThe tools allow for a top-down approach that lets you choose a metric, find the best performing sector and industry, and then find the best stocks in that sector. Not only are these scores easy to understand, but it is easy to compare stocks with each other. You can find the best health care stock or search for the industry with the highest average score. The overall score is a combination of technical and fundamental factors that is a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors besides the overall number before making investment decisions.

What is happening with the shares of Spectrum Pharmaceuticals, Inc. today?

Spectrum Pharmaceuticals, Inc. (SPPI) stock is trading at $ 3.40 at 2:29 p.m. on Tuesday, July 20, a gain of $ 0.10, or 3.03% from the previous closing price of 3 , $ 30. The stock has traded between $ 3.29 and $ 3.42 so far today. The volume today is light. So far 1,040,981 shares have been traded for an average volume of 2,845,494 shares. Click here for the full Spectrum Pharmaceuticals, Inc. stock report.

Source link

Five ways hospitals are tackling pharmaceutical pollution


Pharmaceutical pollution is a growing problem; Not only can pharmaceutical residues harm ecosystems and the environment, but their presence in groundwater, drinking water, soil and more could contribute to the growing threat of antibiotic resistance around the world.

A new report from Health Care Without Harm Europe has examined how hospital wastewater contributes to the amount of pharmaceuticals in the environment and explores the different methods used by European hospitals to reduce the amount of pharmaceutical residues in their waste.

A pilot wastewater treatment plant based on biological processes

Saint-Pierre Ottignies Clinic (CSPO), Belgium

In 2019, CSPO partnered with engineering company John Cockerill Balteau to test pilot wastewater treatment technology designed to treat macro-pollution, pharmaceutical pollution, pathogenic microorganisms and antibiotic-resistant bacteria. in the hospital wastewater.

John Cockerill Balteau’s MEDIX technology is based on biological processes that help eliminate micropollutants in water; using the enzymatic capacities of microorganisms, a wide range of pharmaceutical residues can be biologically degraded and eliminated.

Once broken down, the microorganisms are separated from the treated water by membrane filtration, generating sludge waste that must be incinerated off-site.

The process has been found to remove over 95% of pharmaceutical residues in wastewater.

Peracetic acid to neutralize bacteria resistant to antibiotics

Aarhus University Hospital, Denmark

Aarhus University Hospital began studying how peracetic acid could reduce the level of antibiotic-resistant bacteria in its untreated wastewater in 2019.

The hospital’s research focused on bacteria resistant to ciprofloxacin, as ciprofloxacin is one of the most commonly used antibiotics in hospitals and primary care and is therefore likely to be found at high levels. in hospital wastewater.

The hospital aimed to bring the level of ciprofloxacin-resistant bacteria in its wastewater to the same level as in domestic wastewater after treatment with peracetic acid.

To assess the neutralizing effect of peracetic acid on bacteria resistant to ciprofloxacin, it was injected directly into untreated hospital wastewater. Tests have shown that peracetic acid at different concentrations can achieve a reduction rate of between 98% and 99.9% of bacteria resistant to ciprofloxacin after ten minutes.

Urine pockets to keep iodinated contrast media out of the water cycle

MERK’MAL project, Germany

Iodinated contrast media (ICM), contrast agents used for medical x-ray imaging, are typically excreted in sewage systems via human urine within 24 hours of consumption. Since ICM cannot be completely removed by treatment plants, substances enter the water cycle and accumulate over time.

Although MCIs are not considered toxicologically harmful, health risks cannot be completely excluded. For example, drinking water containing ICM could be of concern; chlorination of water containing a high concentration of the iopamidol contrast agent can lead to the formation of toxic by-products.

The MERK’MAL project was started by the IWW Water Center in 2017 to determine if urine bags would be a cost-effective way to reduce ICM in water.

The project focused on an area around two hospitals and two radiology practices: St Marien-Hospital Mülheim an der Ruhr, Evangelisches Krankenhaus Mülheim, Radiologische Gemeinschaftspraxis Mülheim and Medizinisches Versorgungszentrum Mülheim an der Ruhr.

The researchers behind the project observed a significant reduction in ICM concentrations in the effluents of the local wastewater treatment plant. It was estimated that the use of urine bags could prevent the release of 270 kg of ICM into the water of the surrounding city each year.

Thermal plasma to degrade pharmaceutical residues

Radboud University Medical Center (Radboudumc), The Netherlands

MEDUWA-Vecht (e) is a collaboration between 27 Dutch and German companies, universities, hospitals and governmental and non-governmental organizations to develop solutions to reduce or prevent contamination of water, soil and food by drugs and multidrug-resistant microorganisms.

Radboudumc joined the project in 2014 and partnered with Dutch company VitalFluid to determine whether plasma water activation could effectively degrade pharmaceutical residues from hospital wastewater before it enters the system. sewers.

Plasma water activation is an advanced oxidation process that increases reactive oxygen and nitrogen species that dissolve in water and break down contaminants. Radboudumc researchers studied the efficiency of thermal plasma in breaking down 14 pharmaceutical compounds commonly found in the Vechte River, compared to a more conventional treatment technique.

In the study, all of the pharmaceutical compounds in the water were reduced or completely degraded by both the 150W thermal plasma and UV / H2O2 treatment.

A test bed of good practices to reduce pharmaceutical pollution

Caithness General Hospital (CGH), United Kingdom

The One Health Breakthrough Partnership (OHBP) was a collaboration between the NHS Highland, Scottish Water, the Scottish Environment Protection Agency, HIE, the James Hutton Institute and the Environmental Research Institute at the University of the Highlands and Islands, aimed at a product non-toxic environment in the Scottish Highlands. One of the main goals of the collaboration was the impact of pharmaceuticals on the aquatic environment.

OHBP partners conducted research at CGH, a rural hospital, evaluating the effectiveness of the local wastewater treatment plant in removing eight pharmaceutical residues: diclofenac, ibuprofen, paracetamol, clarithromycin, trimethoprim, carbamazepine, fluoxetine and 17- alpha-ethinylestradiol.

All compounds, except 17-Alpha-ethinylestradiol, were detected in the wastewater of the hospital and the local treatment plant. The plant has been shown to have a varying ability to remove pharmaceutical contaminants from water before it is released.

In response to the findings, the NHS Highland developed an action plan to reduce pharmaceutical pollution, including: a drug waste ‘amnesty’ program to prevent unused drugs from being dumped into drug supply systems. water, raising awareness through educational tools and public messages, substituting damaging drugs for less toxic ones and testing an innovative wastewater treatment filter to remove pharmaceutical contaminants.

After being used as a test bed for the project to remove pharmaceuticals from the environment, CGH became the first hospital in the world to achieve the Alliance of Water Stewardship Standard.

Source link

TIL-Based Therapies Market, 2030 – ResearchAndMarkets.com


DUBLIN – (COMMERCIAL THREAD) – The report “TIL-based Therapies Market by Target Indications, Key Players and Key Geographies: Industry Trends and Global Forecast, 2021-2030” has been added to ResearchAndMarkets.com offer.

The “Til-based Therapies Market Global Forecast 2021-2030” report presents an in-depth study of the current market landscape and future potential of TIL therapies. The report highlights the efforts of industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry.

The contemporary market for TIL-based therapies is characterized by a healthy and growing pipeline of nearly 60 product candidates; in fact, more than 28 of these therapies, including CCRT + TIL (Sun Yat-sen University), Lifileucel (Iovance Biotherapeutics), LTX-315 and TILs (Lytix Biopharma / Herlev Hospital) and IOV-2001 (Iovance Biotherapeutics), are at advanced stages of development.

The first TIL-based therapy, LN-145 under development by Iovance Biotherapeutics, is expected to be approved in 2022. Given the therapeutic benefits they have displayed so far, lucrative opportunities are likely to await the companies. with the capabilities required to develop and manufacture TIL-based therapies for the foreseeable future.

Over time, the clinical success of several TIL-based immunotherapy candidates has inspired many research groups around the world to focus their efforts on this relatively new class of cancer therapies. After 2014, interest in T cell therapies, including those involving TILs, increased exponentially.

In addition, a substantial body of evidence supporting the therapeutic benefits of TIL-based therapies has prompted the establishment of many strategic partnerships (focused on therapy development and clinical research) and has prompted several public and private investors to invest significant capital in innovative companies involved. in this domain.

Promising clinical results and ongoing technical developments, coupled with growing interest from biopharmaceutical developers, should enable the rapid progression of pipeline candidates to higher stages of development and eventually to the market. We are led to believe that the global TIL-based therapy market is poised to experience significant growth for the foreseeable future.

One of the main objectives of the report was to estimate the size of the existing market and identify potential growth opportunities for TIL-based therapies over the next decade. Based on several parameters, such as target consumer segments, region-specific adoption rates and expected prices of these products, we have developed informed estimates of the likely evolution of the market during the period. 2021-2030.

The report also includes probable sales forecasts for TIL-based therapies which are in intermediate or advanced stages of development.

Scope of the report

Among other elements, the report includes the following:

  • A detailed assessment of the current TIL-based therapies market landscape with respect to type of developer (industry / non-industry), stage of development (preclinical, phase I, phase I / II and phase II), therapeutic area (hematological cancer, solid tumor and others), popular target indications (melanoma, ovarian cancer, pancreatic cancer, head and neck cancer, sarcoma, colon cancer, acute myeloid leukemia, cancer of the stomach, chronic lymphocytic leukemia, cervical cancer, breast cancer and others), source of T cells (autologous and allogeneic), frequency of administration (single dose, multiple dose and split dose), segment of target patients (children, adults and elderly patients) and the type of treatment (monotherapy and combination therapy). In addition, the chapter provides details on the most active players (in terms of number of pipeline candidates) engaged in this field.

  • An analysis highlighting the main opinion leaders (KOLs) in this field. It includes a matrix 22 evaluating the relative experience of the preselected KOLs based on their contributions (in terms of involvement in various clinical studies) in this field, and a schematic representation of the world map, indicating the geographical location of the scientists / eminent researchers engaged in the development of therapies based on TIL.

  • Detailed profiles of therapies being evaluated at clinical stages (phase I / II or higher); each profile presents an overview of the therapy, its mechanism of action, current status of development, key clinical trial results, dosing regimen, and manufacturing information.

  • An overview of the main therapeutic areas targeted by TIL-based therapies. It also includes an assessment of the opportunity (in terms of revenue generating potential from sales of therapies) in the indications of oncological diseases.

  • An analysis of partnerships that have been established in the recent past, covering R&D agreements, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements , clinical trial collaborations, product supply management agreements, joint ventures and others.

  • An analysis of investments that have been made in companies that have proprietary products / technologies based on TIL. The different types of funding bodies reported in this area include seed funding, venture capital funding, capital raised through IPOs and subsequent public offerings, grants, and debt financing.

  • A case study on the manufacture of cell therapy products, highlighting the main challenges associated with the production of such therapies. In addition, it presents a detailed list of contractual service providers and in-house manufacturers engaged in this market.

  • An in-depth discussion of various factors that form the basis of cell therapy pricing. It presents different models / approaches that a pharmaceutical company can take, in order to decide the price of a therapy based on TIL.

  • A review of the key promotional strategies that have been adopted by the developers of marketed T cell therapies, namely KYMRIAH and YESCARTA.

For more information on this report, visit https://www.researchandmarkets.com/r/v69rxs

Source link

Relatively Low PE of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) May Provide Opportunity for Investors


This article originally appeared on Simply Wall St News

Vertex Pharmaceuticals Incorporated The stock price (NASDAQ: VRTX) has fallen for most of the year and is now 35% below levels it was trading at in July of last year. On Monday, Vertex announced it was launching a Phase 2 clinical trial program for its VX-548 acute pain treatment, which could lead to renewed interest in the action.

Vertex is currently trading at a PE multiple (price divided by EPS) of 19, which is significantly lower than the biotech multiple of 27.8 PE. The broad market PE is also 19, while the market’s profit growth has been lower than Vertex. This implies that the poor performance of the share price may have created an opportunity for investors.

Vertex’s current portfolio includes several therapies for the treatment of cystic fibrosis. These therapies currently represent all of the company’s revenue and cash flow. In addition to cystic fibrosis therapies, Vertex has an extensive portfolio of new therapies at various stages of development. In October of last year, one of those programs was scrapped due to disappointing data, and the share price immediately fell 20%. Last month, a trial for a similar therapy was also dropped, causing the share price to drop another 10%.

The question now is whether the market overreacted to these two developments. Did two therapies that were in early development really represent 30% of the share price, or did the market overreact to the news?

With earnings growth exceeding that of most other companies lately, Vertex Pharmaceuticals is doing relatively well. Many may expect the strong earnings performance to decline, which has kept the P / E from rising. I hope this is not the case so that you can potentially buy stocks when they are no longer in vogue.

Check out our latest review for Vertex Pharmaceuticals


Keen to know how analysts think the future of Vertex Pharmaceuticals compares to that of the industry? In this case, our free report is a great place to start.

How is the growth of Vertex Pharmaceuticals evolving?

In order to justify its P / E ratio, Vertex Pharmaceuticals should generate growth similar to that of the market.

Looking back, we see that the company increased earnings per share by an impressive 81% last year. Over five years, EPS has increased by an average of 45%. Therefore, it is fair to say that profit growth has recently been superb for the company.

Going forward, EPS is expected to decline slightly in 2022, then grow at an average rate of 36% in 2023 and 2024. Longer term, the growth of the current therapy portfolio is expected to slow as the market becomes saturated. However, if the therapies in development are approved for sale, growth could accelerate again. This gives Vertex an option – the potential for new therapies to drive revenue growth.

Vertex Pharmaceuticals P / E result

As a general rule, we prefer to limit the use of the price / earnings ratio to establishing what the market thinks about the overall health of a business. It can also be used to compare companies to their peers and to the overall market. You can check out other rating metrics that also suggest the stock may be undervalued here.

At first glance, Vertex appears to be attractively valued relative to its industry and the market based on growth prospects. Its cash flow is fairly predictable, and the development pipeline offers an option.

The company will release its quarterly results next week, which could lead to changes in analysts’ estimates for next year. As mentioned, profits are expected to decline slightly next year, so there might also be an opportunity to invest at an attractive price at that time.

Another key area for risk analysis is the company’s balance sheet. You can assess many of the main risks with our free Vertex Pharmaceuticals balance sheet analysis with six simple controls.

If you are uncertain about the strength of Vertex Pharmaceuticals’ business , why not explore our interactive list of stocks with solid trading fundamentals for other companies that you may have missed.

Richard Bowman, Simply Wall St and Simply Wall St analyst not have any position in one of the companies mentioned . This article is general in nature. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents.

Do you have any feedback on this item? Are you worried about the content? Contact us directly. You can also send an email to Editorial-team@simplywallst.com

Source link